PeriVision’s core product, the VisionOne platform, fuses standard VR goggles with advanced artificial-intelligence algorithms to perform visual field examinations that are faster and more comfortable than traditional hospital equipment. Aimed at the world’s 100 million glaucoma patients, the system has already obtained certifications in the EU, the US and the UK, and its first product has been commercially launched. The company plans to broaden VisionOne with new tests for retinal disorders, add AI-driven analytics tools and build deeper clinical-integration solutions. Over the past three years, PeriVision has augmented its development with multiple non-dilutive supports, including EIT Health Wild Card, two Innosuisse project grants, FIT credit, and placements in Switzerland’s TOP100 Startups and Venture Leaders Medtech 2023. The startup is also taking part in Innosuisse Scale-up Coaching and the Biopôle Vanguard Accelerator. With the fresh capital, PeriVision intends to accelerate market expansion across Europe, the United States and the United Kingdom through 2025.

Total raised

$4M

Funding rounds

3

Latest round

Seed

Latest activity

Sep 2025